AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)

AstraZeneca (AZN) announced its key CARDIO-TTRansform Phase III trial missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities claims on behalf of affected AZN investors.

AstraZeneca PLC (NYSE: AZN) faces a securities investigation after shares fell more than 8.3% in early trading on July 9, 2026. If you purchased AstraZeneca shares and suffered a loss, you are encouraged to check your eligibility to recover losses now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

Wainua, a gene-silencing drug for transthyretin-mediated amyloid cardiomyopathy, had been positioned as a key value driver toward AstraZeneca's stated "$80 billion 2030 ambition." The Company referred to the trial as the "largest trial in this population" with the "potential to address key questions" unanswered in the community.

On July 9, 2026, AstraZeneca reported that the trail had failed, noting that "adding Wainua did not provide a statistically significant benefit on the composite outcome of CV mortality and recurrent CV events." If you purchased AstraZeneca shares and lost money, submit your information to preserve your rights. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.